{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:51:07Z","timestamp":1790743867588,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Health and Labour Sciences Research","award":["JPH27-029"],"award-info":[{"award-number":["JPH27-029"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to investigate the clinical characteristics, treatment and prognosis of juvenile idiopathic inflammatory myopathies (JIIM) in Japan for each myositis-specific autoantibody (MSA) profile.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multicentre, retrospective study was conducted using data of patients with JIIM at nine paediatric rheumatology centres in Japan. Patients with MSA profiles, determined by immunoprecipitation using stored serum from the active stage, were included.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>MSA were detected in 85 of 96 cases eligible for the analyses. Over 90% of the patients in this study had one of the following three MSA types: anti-melanoma differentiation-associated protein 5 (MDA5) (n\u2009=\u200931), anti-transcriptional intermediary factor 1 alpha and\/or gamma subunits (TIF1\u03b3) (n\u2009=\u200925) and anti-nuclear matrix protein 2 (NXP2) (n\u2009=\u200925) antibodies. Gottron papules and periungual capillary abnormalities were the most common signs of every MSA group in the initial phase. The presence of interstitial lung disease (ILD) was the highest risk factor for patients with anti-MDA5 antibodies. Most patients were administered multiple drug therapies: glucocorticoids and MTX were administered to patients with anti-TIF1\u03b3 or anti-NXP2 antibodies. Half of the patients with anti-MDA5 antibodies received more than three medications including i.v. CYC, especially patients with ILD. Patients with anti-MDA5 antibodies were more likely to achieve drug-free remission (29 vs 21%) and less likely to relapse (26 vs 44%) than others.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Anti-MDA5 antibodies are the most common MSA type in Japan, and patients with this antibody are characterized by ILD at onset, multiple medications including i.v. CYC, drug-free remission, and a lower frequency of relapse. New therapeutic strategies are required for other MSA types.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab108","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T18:57:13Z","timestamp":1612378633000},"page":"4821-4831","source":"Crossref","is-referenced-by-count":41,"title":["Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1765-1494","authenticated-orcid":false,"given":"Yuichi","family":"Yamasaki","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Kagoshima University Hospital, Kagoshima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimoto","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shinshu University School of Medicine, Matsumoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9017-3842","authenticated-orcid":false,"given":"Shinji","family":"Akioka","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7926-0475","authenticated-orcid":false,"given":"Kazuko","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Allergology, Department of Internal Medicine, St Marianna University School of Medicine, Kawasaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0425-4097","authenticated-orcid":false,"given":"Shunichiro","family":"Takezaki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hokkaido University Hospital, Sapporo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Nakaseko","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Aichi Children\u2019s Health and Medical Center, Obu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Aichi Children\u2019s Health and Medical Center, Obu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medicine, Gunma University, Maebashi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Immunology, Saitama Children\u2019s Medical Center, Saitama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7208-1562","authenticated-orcid":false,"given":"Takayuki","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Tokyo Women\u2019s Medical University, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-060X","authenticated-orcid":false,"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Rheumatic Diseases, Kyoto University, Kyoto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Ohta","sequence":"additional","affiliation":[{"name":"Division of Public Health, Department of Social Medicine, Saitama Medical University Faculty of Medicine, Moroyama, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"2021100217423238900_keab108-B1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/25785826.2018.1531188","article-title":"Clinical significance of myositis specific autoantibodies","volume":"41","author":"Nakashima","year":"2018","journal-title":"Immunol Med"},{"key":"2021100217423238900_keab108-B2","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"key":"2021100217423238900_keab108-B3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"2021100217423238900_keab108-B4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"2021100217423238900_keab108-B5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"2021100217423238900_keab108-B6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpeds.2017.01.046","article-title":"Childhood Arthritis and Rheumatology Research Alliance Legacy Registry Investigators. Race, income, and disease outcomes in juvenile dermatomyositis","volume":"184","author":"Phillippi","year":"2017","journal-title":"J Pediatr"},{"key":"2021100217423238900_keab108-B7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","article-title":"Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis","volume":"54","author":"Kobayashi","year":"2015","journal-title":"Rheumatology (Oxford"},{"key":"2021100217423238900_keab108-B8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14397595.2018.1452353","article-title":"Myositis specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies","volume":"29","author":"Ueki","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2021100217423238900_keab108-B9","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/14397595.2018.1511025","article-title":"Clinical subsets of juvenile dermatomyositis classified by myositis specific autoantibodies: experience at a single center in Japan","volume":"29","author":"Iwata","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2021100217423238900_keab108-B10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.21037\/atm.2017.03.94","article-title":"MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis","volume":"5","author":"Sontheimer","year":"2017","journal-title":"Ann Transl Med"},{"key":"2021100217423238900_keab108-B11","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/art.1780281207","article-title":"Detection of antibodies to small nuclear ribonucleoproteins and small cytoplasmic ribonucleoproteins using unlabeled cell extracts","volume":"28","author":"Forman","year":"1985","journal-title":"Arthritis Rheum"},{"key":"2021100217423238900_keab108-B12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3109\/14397595.2014.896494","article-title":"Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients","volume":"24","author":"Kang","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2021100217423238900_keab108-B13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","article-title":"Anti-CADM\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease","volume":"23","author":"Sato","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2021100217423238900_keab108-B14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/09114300.2018.1451591","article-title":"Pediatric rheumatic diseases: a review regarding the improvement of long-term prognosis and the transition to adults","volume":"41","author":"Mori","year":"2018","journal-title":"Immunol Med"},{"key":"2021100217423238900_keab108-B15","first-page":"1","article-title":"2019 Diagnostic criteria for mixed connective tissue disease (MCTD): from the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases","volume":"7","author":"Tanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2021100217423238900_keab108-B16","article-title":"Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America","author":"Mamyrova","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2021100217423238900_keab108-B17","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021100217423238900_keab108-B18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2021100217423238900_keab108-B19","doi-asserted-by":"crossref","first-page":"e15578","DOI":"10.1097\/MD.0000000000015578","article-title":"Clinical significance of myositis specific autoantibody profiles in Japanese patients with polymyositis\/dermatomyositis","volume":"28","author":"Temmoku","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2021100217423238900_keab108-B20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies denine useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine (Baltimore"},{"key":"2021100217423238900_keab108-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021100217423238900_keab108-B22","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2021100217423238900_keab108-B23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/nan.12498","article-title":"Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis","volume":"45","author":"Soponkanaporn","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2021100217423238900_keab108-B24","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2021100217423238900_keab108-B25","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2021100217423238900_keab108-B26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/14397595.2014.900843","article-title":"Serum interferon-alpha is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis","volume":"25","author":"Horai","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2021100217423238900_keab108-B27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/joim.13154","article-title":"IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis\/dermatomyositis","volume":"289","author":"Shimizu","year":"2020","journal-title":"J Intern Med"},{"key":"2021100217423238900_keab108-B28","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/art.34657","article-title":"Brief report: association of HLA-DRB10101\/0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population","volume":"64","author":"Gono","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021100217423238900_keab108-B29","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/annrheumdis-2019-215046","article-title":"Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups","volume":"78","author":"Rothwell","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021100217423238900_keab108-B30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/rheumatology\/keaa436","article-title":"Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America","volume":"60","author":"Sabbagh","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2021100217423238900_keab108-B31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/s10165-012-0637-6","article-title":"Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases","volume":"23","author":"Horai","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2021100217423238900_keab108-B32","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/rheumatology\/kex516","article-title":"Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis","volume":"57","author":"Aouizerate","year":"2018","journal-title":"Rheumatology (Oxford"},{"key":"2021100217423238900_keab108-B33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clim.2018.11.008","article-title":"Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: A meta-analysis of 20 cohorts","volume":"198","author":"Zhong","year":"2019","journal-title":"Clin Immunol"},{"key":"2021100217423238900_keab108-B34","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology (Oxford"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab108\/36198622\/keab108.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/10\/4821\/40500253\/keab108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/10\/4821\/40500253\/keab108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T17:44:57Z","timestamp":1633196697000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/10\/4821\/6129018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,2,5]]},"published-print":{"date-parts":[[2021,10,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab108","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,2,5]]}}}